[PDF][PDF] Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors
A Besse, L Besse, M Kraus, M Mendez-Lopez… - Cell chemical …, 2019 - cell.com
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
[PDF][PDF] Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
PI MM, A Besse, L Besse, M Kraus, E Maurits… - scholarlypublications …
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (b1, b2, b5), while b5 was identified …
proteasome harbors six proteolytically active subunits (b1, b2, b5), while b5 was identified …
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
A Besse, L Besse, M Kraus, M Mendez-Lopez… - Cell chemical …, 2019 - sonar.ch
English Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
[HTML][HTML] Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
A Besse, L Besse, M Kraus, M Mendez-Lopez… - Cell Chemical …, 2019 - Elsevier
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
A Besse, L Besse, M Kraus… - Cell chemical …, 2019 - pubmed.ncbi.nlm.nih.gov
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
A Besse, L Besse, M Kraus, M Mendez-Lopez… - Cell chemical …, 2019 - folia.unifr.ch
English Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
[引用][C] Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
A Besse, L Besse, M Kraus, M Mendez-Lopez… - Cell Chemical …, 2019 - cir.nii.ac.jp
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently
Available Proteasome Inhibitors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Available Proteasome Inhibitors | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
A Besse, L Besse, M Kraus, M Mendez-Lopez… - Cell Chemical …, 2019 - europepmc.org
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors
A Besse, L Besse, M Kraus… - Cell …, 2019 - scholarlypublications …
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …